# TCF7L2 Insoforms in Canonical Wnt Signaling During Cardiac Hpertrophy & Failure

> **NIH NIH R01** · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · 2024 · $482,059

## Abstract

Project summary
Heart failure is a major health problem and its underlying molecular mechanisms remain poorly defined,
hampering and delaying the development of effective and targeted therapies for clinical patient management.
During the pathogenesis of many heart diseases, fetal genes and developmental signals are re-activated. The
canonical Wnt/β-catenin pathway is one of the most diverse signaling networks and has been implicated in
many human diseases as well as almost every aspect of development. Our data have revealed that canonical
Wnt/β-catenin signaling plays a key role in human and animal models of heart failure. However, it is not clear
how β-catenin signaling is transmitted to the transcriptional machinery for fetal gene reprograming. Our data
has revealed that TCF7L2 isoforms are the major and essential nuclear organizers that assemble the β-
catenin-mediated transcriptional complex. We have identified major cardiac-specific TCF7L2 isoforms
expressed in different stages of heart development and hypothesize that differential expression of TCF7L2
isoforms dictates the context-specific gene targets of cardiac Wnt signaling. More importantly, fetal TCF7L2
isoforms are active in failing human hearts. In this proposal, we will profile cardiac-specific TCF7L2 isoforms
and their target genes in human hearts. Moreover, we will create mouse models to determine whether TCF7L2
is necessary for heart failure development after pressure overload or sufficient to induce heart failure when
overexpressed according to Koch’s postulates for identifying the causative agents of a disease. Finally, we will
evaluate if pharmacologic intervention to interfere TCF7L2 interaction with β-catenin can prevent heart failure
after pressure overload or TCF7L2 overexpression. Our goal is to determine if manipulating β-catenin signal
transduction by targeting unique function domains of cardiac-specific TCF7L2 isoforms can efficiently prevent
or even reverse cardiac remodeling and heart failure.

## Key facts

- **NIH application ID:** 10815735
- **Project number:** 5R01HL153403-05
- **Recipient organization:** UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
- **Principal Investigator:** Faqian Li
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $482,059
- **Award type:** 5
- **Project period:** 2021-04-01 → 2026-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10815735

## Citation

> US National Institutes of Health, RePORTER application 10815735, TCF7L2 Insoforms in Canonical Wnt Signaling During Cardiac Hpertrophy & Failure (5R01HL153403-05). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10815735. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*